Acute Coronary Syndrome

Clinical Trial Finder

Many patients with acute coronary syndrome are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

An Epidemiological Cohort Study of Acute Coronary Syndromes in The Greek Population. The PHAETHON Study

Condition:   Coronary Artery Disease
Intervention:  
Sponsor:   Hellenic Cardiovascular Research Society
Completed - verified April 2015

Different Doses of Rosuvastatin Therapy on Regression of Critical Coronary Atherosclerosis in ACS Patients

Condition:   Acute Coronary Syndrome
Intervention:   Drug: rosuvastatin
Sponsor:   Beijing Friendship Hospital
Not yet recruiting - verified April 2015

Study Apixaban to Vitamin K Antagonist for the Prevention of Stroke or Systemic Embolism and Bleeding in Patients With Non-valvular Atrial Fibrillation and Acute Coronary Syndrome/Percutaneous Coronary Intervention

Condition:   Acute Coronary Syndromes
Interventions:   Drug: Apixaban;   Drug: vitamin K antagonist;   Drug: Acetylsalicylic acid;   Other: Acetylsalicylic acid placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke Clinical Research Institute
Not yet recruiting - verified April 2015

Researches of Retinal Artery Lesions and Acute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsor:   Capital Medical University
Active, not recruiting - verified April 2015

Non-contrast Cardiac CT as a Risk Stratification Tool in Patients With Non-cardiac Chest Pain

Condition:   Coronary Artery Disease
Intervention:   Other: Non-contrast Cardiac CT scan
Sponsor:   University of Southern Denmark
Recruiting - verified April 2015

An Observational Prospective Study to Understand the Usage Pattern of Ticagrelor With ACS (Acute Coronary Syndrome)

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsor:   AstraZeneca
Not yet recruiting - verified April 2015

Dose-escalation, Repeated and Single Oral Dosing Study

Condition:   Acute Coronary Syndrome
Interventions:   Drug: APD791;   Drug: Clopidogrel;   Drug: Aspirin;   Drug: Placebo for APD791
Sponsors:   IlDong Pharmaceutical Co Ltd;   Asan Medical Center
Enrolling by invitation - verified April 2015

Trans-pulmonary Pressure in ARDS

Condition:   Acute Respiratory Distress Syndrome
Interventions:   Device: level of positive end expiratory pressure (Prone Proseva);   Device: level of positive end expiratory pressure (Prone Talmor)
Sponsor:   Hospices Civils de Lyon
Not yet recruiting - verified April 2015

Jakarta Acute Coronary Syndrome Registry

Condition:   Acute Coronary Syndrome
Intervention:   Other: JAC Registry
Sponsor:   National Cardiovascular Center Harapan Kita Hospital Indonesia
Recruiting - verified April 2015

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Acetylsalicylic acid;   Drug: Rivaroxaban;   Drug: Clopidogrel;   Drug: Ticagrelor
Sponsors:   Janssen Research & Development, LLC;   Bayer;   Duke Clinical Research Institute;   Harvard Medical School
Not yet recruiting - verified April 2015

RuSsian RegisTry of Acute CoronaRy SyndromE TreAtMent and Approach in Dual Antiplatelet Therapy

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified April 2015

Tako-Tsubo Cardiomyopathy and Cardiac Syndrome X: New Insights Into the Pathophysiology

Conditions:   Syndrome X;   Takotsubo Cardiomyopathy
Intervention:   Other: BaroReflex Sensitivity, endothelial function measurement
Sponsor:   Ospedale San Giovanni Bellinzona
Active, not recruiting - verified April 2015

Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified April 2015

Selective Depletion of CD45RA+ Naive T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors for Prevention of GVHD

Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Biphenotypic Leukemia;   Acute Leukemia of Ambiguous Lineage;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Graft Versus Host Disease;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Refractory Anemia With Excess Blasts
Interventions:   Radiation: Total-Body Irradiation;   Drug: Fludarabine Phosphate;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Other: Laboratory Biomarker Analysis
Sponsors:   Fred Hutchinson Cancer Research Center;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI)
Recruiting - verified April 2015

Osteopathic Treatment and Deep Vein Thrombosis (DVT)

Condition:   Deep Vein Thrombosis (DVT)
Intervention:   Other: Osteopathic Treatment
Sponsor:   Capital District Health Authority, Canada
Recruiting - verified April 2015

MT2013-31:Allo BMT for Metabolic Disorders, Osteopetrosis and Males With Rett Syndrome

Conditions:   Mucopolysaccharidosis I;   Mucopolysaccharidosis II;   Mucopolysaccharidosis VI;   Mucopolysaccharidosis VII;   Hurler Syndrome;   Hunter Syndrome;   Maroteaux Lamy Syndrome;   Sly Syndrome;   Glycoprotein Metabolic Disorders;   Alpha Mannosidosis;   Fucosidosis;   Aspartylglucosaminuria;   Adrenoleukodystrophy;   Peroxisomal Disorders;   Osteopetrosis;   Rett Syndrome;   Sphingolipidosis;   Gangliosidosis;   Globoid Cell Leukodystrophy;   Metachromatic Leukodystrophy;   Niemann Pick B;   Niemann Pick C Subtype 2;   I-cell Disease
Interventions:   Procedure: blood stem cell transplant;   Drug: Rabbit Anti-Thymocyte Globulin (ATG);   Drug: Fludarabine;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Cyclosporine A (CSA);   Drug: Methylprednisolone;   Drug: Mycophenolate Mofetil (MMF);   Drug: Granulocyte-Colony Stimulating Factor (G-CSF);   Drug: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF);   Drug: N-acetylcysteine;   Drug: Celecoxib;   Drug: Vitamin E;   Drug: Alpha Lipoic Acid
Sponsor:   Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2015

VTEval Project - Prospective Cohort Studies to Evaluate and Improve Diagnostics, Management Strategies and Risk Stratification in VTE

Conditions:   Venous Thromboembolism (VTE);   Deep Vein Thrombosis (DVT);   Pulmonary Embolism (PE)
Intervention:  
Sponsor:   Johannes Gutenberg University Mainz
Recruiting - verified April 2015

Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified April 2015

ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial

Condition:   End Stage Renal Failure on Dialysis
Interventions:   Drug: Spironolactone;   Drug: Placebo
Sponsors:   University Hospital, Brest;   Central Hospital, Nancy, France;   Institut National de la Santé Et de la Recherche Médicale, France
Recruiting - verified April 2015

Preventing Stem Cell Transplant Complications With a Blood Separator Machine

Conditions:   MDS (Myelodysplastic Syndrome);   Myeloproliferative Disorder;   Lymphoma, Non-Hodgkin;   ALL (Acute B-Lymphoblastic Leukemia);   AML (Acute Meylogenous Leukemia
Intervention:   Device: Graft Manipulation (CD34+ Selection)
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2015

Mechanisms of Vasovagal Syncope

Conditions:   Vasovagal Syncope;   Postural Tachycardia Syndrome
Interventions:   Drug: Phenylephrine;   Drug: L-Ng-monomethyl Arginine (L-NMMA)
Sponsor:   New York Medical College
Recruiting - verified April 2015

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: alirocumab SAR236553 (REGN727);   Other: placebo
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified April 2015

Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis

Condition:   Coronary Artery Bypass
Interventions:   Drug: Prasugrel;   Drug: Placebo
Sponsor:   Department of Veterans Affairs
Recruiting - verified April 2015

Fondaparinux EU-RMP (Adherence)

Conditions:   ST-elevation Myocardial Infarction;   Unstable Angina;   Non ST Segment Elevation Myocardial Infarction;   Acute Coronary Syndrome
Intervention:   Drug: fondaparinux
Sponsor:   GlaxoSmithKline
Completed - verified April 2015

Remote Ischemic Preconditioning in High Risk Cardiovascular Surgery Patients

Conditions:   Death;   Stroke;   Low Cardiac Output Syndrome;   Myocardial Infarction;   Renal Failure;   Pulmonary Failure
Interventions:   Other: Remote ischemic preconditioning stimulus;   Other: control
Sponsor:   Queen's University
Recruiting - verified April 2015

Extended Drug Utilization Study Among Patients Exposed to Ticagrelor, Clopidogrel and Prasugrel

Condition:   Bleeding ,Arrhythmias, Heart Failure, Acute Renal Failure, Acute Liver Failure, Dyspnoea, Gout
Intervention:   Drug: Risk of selected safety events
Sponsor:   AstraZeneca
Completed - verified April 2015

Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis

Conditions:   Aortocoronary Saphenous Vein Bypass Graft Atherosclerosis;   Intermediate Saphenous Vein Graft Lesions
Intervention:   Drug: extended-release niacin (Niaspan)
Sponsors:   North Texas Veterans Healthcare System;   National Institutes of Health (NIH);   National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting - verified April 2015

Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty

Condition:   Saphenous Vein Graft Atherosclerosis
Interventions:   Device: Bare Metal Stent;   Device: Drug-Eluting Stent;   Drug: Blinded clopidogrel;   Drug: Placebo;   Drug: Thienopyridine (open-label)
Sponsor:   Department of Veterans Affairs
Recruiting - verified April 2015

Troponin T as Risk Stratification Tool in Peripheral Arterial Occlusive Disease

Condition:   Peripheral Arterial Occlusive Disease
Intervention:  
Sponsors:   Heart Center Bad Krozingen;   Johann Wolfgang Goethe University Hospitals
Completed - verified April 2015

A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)

Conditions:   Myelodysplastic Syndromes;   Thrombocytopenia
Intervention:   Drug: Eltrombopag
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2015

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Conditions:   Anemia;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome
Interventions:   Biological: Epoetin Alfa;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified April 2015

Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coronary Syndrome: The ZESCA Trial

Conditions:   Acute Coronary Syndrome;   Myocardial Infarction;   Smoking
Interventions:   Drug: Bupropion HCl ER;   Drug: Placebo
Sponsors:   Mark Eisenberg;   Canadian Institutes of Health Research  (CIHR);   Heart and Stroke Foundation of Canada
Completed - verified April 2015

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Conditions:   B-cell Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions:   Drug: doxorubicin hydrochloride;   Radiation: 3-dimensional conformal radiation therapy;   Drug: cytarabine;   Drug: dexamethasone;   Drug: pegaspargase;   Drug: methotrexate;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: cyclophosphamide;   Drug: thioguanine;   Drug: vincristine sulfate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Active, not recruiting - verified April 2015

Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission

Conditions:   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Adult Acute Megakaryoblastic Leukemia;   Adult Acute Monocytic Leukemia;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With Maturation;   Adult Acute Myeloid Leukemia With Minimal Differentiation;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL;   Adult Acute Myeloid Leukemia Without Maturation;   Adult Acute Myelomonocytic Leukemia;   Adult Erythroleukemia;   Adult Pure Erythroid Leukemia;   Alkylating Agent-Related Acute Myeloid Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts in Transformation
Interventions:   Procedure: Clinical Observation;   Drug: Tipifarnib
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting - verified December 2014

Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow

Conditions:   Hematologic Disease;   Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndrome;   Myeloproliferative Disorder
Intervention:   Procedure: Stem cell transplantation
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified August 2014

Get CardioSmart

You're Invited